Julius Strauss

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 10

Top Topics

Prostate Cancer

Top Venues

Journal for immunotherapy of cancer

Experimental biology and medicine (Maywood, N.J.)

Pharmacogenomics

This page only lists publications with an associated author ORCID identifier.

Publications

Julius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K Pachynski, Theodore S Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee N Donahue, Yo-Ting Tsai, XiaoZhe Wang, Yulia Vugmeyster, Frank Beier, Joerg Seebeck, Andreas Schroeder, Sarah Chennoufi, James L Gulley
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma. Journal for immunotherapy of cancer 11 (5) (2023)
Jason Mark Redman, Geraldine O'Sullivan Coyne, Clay T Reed, Ravi A Madan, Julius Strauss, Seth J Steinberg, Jennifer Marté, Lisa M Cordes, Christopher Heery, James L Gulley
Avelumab in Patients With Metastatic Colorectal Cancer. The oncologist (2023)
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M Geynisman, Matthew Zibelman, Tina Mayer, Julius Strauss, Gang Chen, Myrna Rauckhorst, Sheri McMahon, Anna Couvillon, Seth Steinberg, William D Figg, William L Dahut, Jeffrey Schlom, James L Gulley
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. The oncologist (2023)
Thomas A Odeny, Kathryn Lurain, Julius Strauss, Steven P Fling, Elad Sharon, Anna Wright, Javier Martinez-Picado, Teresa Morán, James L Gulley, Maria Gonzales Cao, Thomas S Uldrick, Robert Yarchoan, Ramya Ramaswami
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer. Journal for immunotherapy of cancer 10 (9) (2023)
Margaret E Gatti-Mays, Nicholas P Tschernia, Julius Strauss, Ravi A Madan, Fatima H Karzai, Marijo Bilusic, Jason Mark Redman, Houssein Abdul Sater, Charalampos S Floudas, Nicole J Toney, Renee N Donahue, Caroline Jochems, Jennifer L Marté, Deneise Francis, Sheri McMahon, Elizabeth Lamping, Lisa M Cordes, Jeffrey Schlom, James L Gulley
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors. The oncologist (2023)
Yo-Ting Tsai, Julius Strauss, Nicole J Toney, Caroline Jochems, David J Venzon, James L Gulley, Jeffrey Schlom, Renee N Donahue
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. Journal for immunotherapy of cancer 10 (4) (2022)
John S Davies, Farrah Karimipour, Ling Zhang, Nisha Nagarsheth, Scott M Norberg, Carylinda Serna, Julius Strauss, Shinheng Chiou, James L Gulley, Christian S Hinrichs
Non-synergy of PD-1 blockade with T-cell therapy in solid tumors. Journal for immunotherapy of cancer 10 (7) (2022)
Sofia R Gameiro, Julius Strauss, James L Gulley, Jeffrey Schlom
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status. Experimental biology and medicine (Maywood, N.J.) 247 (13) (2022)
Peter Joseph DeMaria, Marijo Bilusic, Deric M Park, Christopher R Heery, Renee N Donahue, Ravi A Madan, Mohammad Hadi Bagheri, Julius Strauss, Victoria Shen, Jennifer L Marté, Seth M Steinberg, Jeffrey Schlom, Mark R Gilbert, James L Gulley
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable Chordoma. The oncologist 26 (5) (2021)
Tristan M Sissung, Lisa M Cordes, Cody J Peer, Shruti Gandhy, Jason Mark Redman, Julius Strauss, William Douglas Figg
Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD. Pharmacogenomics 22 (2) (2020)